Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2016’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)

The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects

The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Advanced Accelerator Applications S.A.

Advenchen Laboratories, LLC

Ariad Pharmaceuticals, Inc.

Arog Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma Inc.

Astex Pharmaceuticals Inc

Blueprint Medicines Corporation

Boston Biomedical, Inc.

Calithera Biosciences, Inc.

Chipscreen Biosciences Ltd

Daiichi Sankyo Company, Limited

Deciphera Pharmaceuticals, LLC

F. Hoffmann-La Roche Ltd.

Horizon Pharma Plc

Immunicum AB

Jiangsu Hengrui Medicine Co., Ltd.

Kolltan Pharmaceuticals, Inc.

Natco Pharma Limited

Nerviano Medical Sciences S.r.l.

Novartis AG

Omeros Corporation

Plexxikon Inc.

Rhizen Pharmaceuticals S.A.

Taiho Pharmaceutical Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Gastrointestinal Stromal Tumor (GIST) Overview 10

Therapeutics Development 11

Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 11

Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 12

Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 13

Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 15

Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19

Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 21

Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 22

AB Science SA 22

Advanced Accelerator Applications S.A. 23

Advenchen Laboratories, LLC 24

Ariad Pharmaceuticals, Inc. 25

Arog Pharmaceuticals, Inc. 26

ArQule, Inc. 27

Array BioPharma Inc. 28

Astex Pharmaceuticals Inc 29

Blueprint Medicines Corporation 30

Boston Biomedical, Inc. 31

Calithera Biosciences, Inc. 32

Chipscreen Biosciences Ltd 33

Daiichi Sankyo Company, Limited 34

Deciphera Pharmaceuticals, LLC 35

F. Hoffmann-La Roche Ltd. 36

Horizon Pharma Plc 37

Immunicum AB 38

Jiangsu Hengrui Medicine Co., Ltd. 39

Kolltan Pharmaceuticals, Inc. 40

Natco Pharma Limited 41

Nerviano Medical Sciences S.r.l. 42

Novartis AG 43

Omeros Corporation 44

Plexxikon Inc. 45

Rhizen Pharmaceuticals S.A. 46

Taiho Pharmaceutical Co., Ltd. 47

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Combination Products 49

Assessment by Target 50

Assessment by Mechanism of Action 53

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

alpelisib - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

amcasertib - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

apatinib - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

ARQ-092 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

binimetinib - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

BLU-285 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

buparlisib hydrochloride - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

CB-839 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

CHMFLKIT-110 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

crenolanib besylate - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

CS-2164 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

DCC-2618 - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

everolimus - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

infigratinib - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

interferon gamma-1b - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

Intuvax - Drug Profile 123

Product Description 123

Mechanism Of Action 123

R&D Progress 123

KTN-0158 - Drug Profile 129

Product Description 129

Mechanism Of Action 129

R&D Progress 129

masitinib - Drug Profile 131

Product Description 131

Mechanism Of Action 131

R&D Progress 131

nilotinib - Drug Profile 144

Product Description 144

Mechanism Of Action 144

R&D Progress 144

NMSP-088 - Drug Profile 149

Product Description 149

Mechanism Of Action 149

R&D Progress 149

NRCAN-019 - Drug Profile 150

Product Description 150

Mechanism Of Action 150

R&D Progress 150

onalespib - Drug Profile 152

Product Description 152

Mechanism Of Action 152

R&D Progress 152

Peptide to Antagonize GRPR for Oncology - Drug Profile 156

Product Description 156

Mechanism Of Action 156

R&D Progress 156

pexidartinib - Drug Profile 157

Product Description 157

Mechanism Of Action 157

R&D Progress 157

PLX-9486 - Drug Profile 161

Product Description 161

Mechanism Of Action 161

R&D Progress 161

ponatinib hydrochloride - Drug Profile 162

Product Description 162

Mechanism Of Action 162

R&D Progress 162

SF-1126 - Drug Profile 175

Product Description 175

Mechanism Of Action 175

R&D Progress 175

SHR-1020 - Drug Profile 177

Product Description 177

Mechanism Of Action 177

R&D Progress 177

Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 179

Product Description 179

Mechanism Of Action 179

R&D Progress 179

Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 180

Product Description 180

Mechanism Of Action 180

R&D Progress 180

TAS-116 - Drug Profile 181

Product Description 181

Mechanism Of Action 181

R&D Progress 181

TGR-1202 - Drug Profile 182

Product Description 182

Mechanism Of Action 182

R&D Progress 182

vemurafenib - Drug Profile 189

Product Description 189

Mechanism Of Action 189

R&D Progress 189

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 196

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 197

Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 198

Featured News & Press Releases 198

Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 198

Jul 13, 2016: Boston Biomedical Announces Generic Name of BBI-503: Amcasertib 198

May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting 199

Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting 200

Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 201

Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 201

Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 202

Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 202

Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 203

Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 204

Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 205

Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 206

Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 206

Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor 207

Feb 01, 2012: AB Science Reports Encouraging Results From Phase II Study With Its Investigational Drug, Masitinib 207

Appendix 209

Methodology 209

Coverage 209

Secondary Research 209

Primary Research 209

Expert Panel Validation 209

Contact Us 209

Disclaimer 210

List of Tables

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016 11

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Gastrointestinal Stromal Tumor (GIST) – Pipeline by AB Science SA, H2 2016 22

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advanced Accelerator Applications S.A., H2 2016 23

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advenchen Laboratories, LLC, H2 2016 24

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 25

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Arog Pharmaceuticals, Inc., H2 2016 26

Gastrointestinal Stromal Tumor (GIST) – Pipeline by ArQule, Inc., H2 2016 27

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Array BioPharma Inc., H2 2016 28

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Astex Pharmaceuticals Inc, H2 2016 29

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Blueprint Medicines Corporation, H2 2016 30

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Boston Biomedical, Inc., H2 2016 31

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Calithera Biosciences, Inc., H2 2016 32

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Chipscreen Biosciences Ltd, H2 2016 33

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 35

Gastrointestinal Stromal Tumor (GIST) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Horizon Pharma Plc, H2 2016 37

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Immunicum AB, H2 2016 38

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 40

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Natco Pharma Limited, H2 2016 41

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 42

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Novartis AG, H2 2016 43

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Omeros Corporation, H2 2016 44

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Plexxikon Inc., H2 2016 45

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 46

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 47

Assessment by Monotherapy Products, H2 2016 48

Assessment by Combination Products, H2 2016 49

Number of Products by Stage and Target, H2 2016 51

Number of Products by Stage and Mechanism of Action, H2 2016 54

Number of Products by Stage and Route of Administration, H2 2016 58

Number of Products by Stage and Molecule Type, H2 2016 60

Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, H2 2016 196

Gastrointestinal Stromal Tumor (GIST) – Discontinued Products, H2 2016 197

List of Figures

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016 11

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 48

Number of Products by Top 10 Targets, H2 2016 50

Number of Products by Stage and Top 10 Targets, H2 2016 50

Number of Products by Top 10 Mechanism of Actions, H2 2016 53

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 53

Number of Products by Routes of Administration, H2 2016 57

Number of Products by Stage and Routes of Administration, H2 2016 57

Number of Products by Molecule Types, H2 2016 59

Number of Products by Stage and Molecule Types, H2 2016 59

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports